Stay Alert for Safety Issues With Xeljanz and Other "JAK Inhibitors"

October 2019

Questions will pop up about the safety of "Janus kinase (JAK) inhibitors"...Xeljanz, Xeljanz XR, and Olumiant.

There's an uptick in the use of these specialty meds for rheumatoid arthritis and other autoimmune diseases...since they're taken orally.

Now there's a boxed warning about an increased risk of blood clots with Xeljanz or Xeljanz XR (tofacitinib). Olumiant (baricitinib) also carries this warning.

Practical advice for a better career, with unlimited access to CE

Pharmacy Technician's Letter Canada includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 120+ CE courses, including the popular CE-in-the-Letter
  • Helpful, in-depth Technician Tutorials
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get a quote